FOLH1 and metastatic neoplasm: In contrast to EpCAM, which is thought to be downregulated as neoplastic cells begin to exhibit a mesenchymal phenotype [1], PSMA is largely specific to prostate cells while its expression increases progressively in higher grade PC, metastatic disease and CRPC [40].